What 8 Analyst Ratings Have To Say About Sage Therapeutics
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:
RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $48
RBC Capital analyst Brian Abrahams maintains Sage Therapeutics (NASDAQ:SAGE) with a Sector Perform and lowers the price target from $52 to $48.
Oppenheimer Maintains Outperform on Sage Therapeutics, Lowers Price Target to $80
Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:SAGE) with a Outperform and lowers the price target from $84 to $80.
HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $55
HC Wainwright & Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $80 to $55.
How Bad Are Sage Therapeutics’s Earnings? | Return On Capital Employed
Sage Therapeutics (NASDAQ:SAGE) brought in sales totaling $1.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 21.17%, resulting in a loss of $130.89 million.
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Sage Therapeutics Q3 EPS $(2.21) Misses $(1.85) Estimate, Sales $1.44M Miss $1.96M Estimate
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.85) by 19.46 percent. This is a 8.87 percent decrease over losses of $(2.03) per share
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
Just before Tuesday’s close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter.